FDA expands Actemra use in rare juvenile RA
This article was originally published in Scrip
Executive Summary
Roche US unit Genentech gained the US FDA's blessing to expand the use of Actemra (tocilizumab) alone or in combination with methotrexate to treat children as young as two years with polyarticular juvenile idiopathic arthritis (PJIA), a form of juvenile rheumatoid arthritis (JRA).